Government-Owned Inventions; Availability for Licensing, 22351-22352 [05-8546]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 82 / Friday, April 29, 2005 / Notices
submit required financial and
performance reports.
Failure to submit required reports
within the time allowed may result in
suspension or termination of an active
grant, withholding of additional awards
for the project, or other enforcement
actions such as withholding of
payments or converting to the
reimbursement method of payment.
Continued failure to submit required
reports may result in the imposition of
special award provisions, or cause other
eligible projects or activities involving
that grantee organization, or the
individual responsible for the
delinquency to not be funded.
Failure to obtain prior approval for
change in Scope, Principal Investigator,
Grantee Institutions, Successor in
Interest, or Recipient Institute Name,
undertaking any activities disapproved
or restricted as a condition of the award,
may result in fund restrictions.
VII. Agency Contact(s)
1. Questions on the initiative,
regarding IHS NARCH issues and
policies, may be directed to: Timothy L.
Taylor, Ph.D., Director of Planning,
Evaluation and Research, Indian Health
Service, 801 Thompson Avenue, TMP,
Suite 450, Rockville, MD 20852–1750,
Telephone: (301) 443–0222, Fax: (301)
443–1522, e-mail: ttaylor@hqe.ihs.gov.
2. Questions on grants management
and fiscal matters may be directed to:
Sylvia Ryan, Division of Grants
Operations, Indian Health Service,
Reyes Building, 801 Thompson Avenue,
Rockville, MD 20852–1627, Telephone:
(301) 443–5204, Fax: (301) 443–9602, email: sryan@hqe.ihs.gov.
3. Questions on NIGMS issues and
policies, may be directed to: Clifton A.
Poodry, Ph.D., Minority Opportunities
in Research Division, National Institute
of General Medical Sciences, 45 Center
Drive, Suite 2AS.37, MSC 6200,
Bethesda, MD 20892–6200, Telephone:
(301) 594–3900, Fax: (301) 480–2753, email: poodryc@nigms.nih.gov.
4. Questions on the review of
Applications may be directed to:
Mushtaq A. Khan, D.V.M., Ph.D., Chief,
Digestive and Respiratory Sciences
IRGs, Center for Scientific Review, MSC
7818, Room 2176; 6701 Rockledge
Drive; Bethesda, MD 20892 (20817 for
Fed Ex) Telephone: (301) 435–1778;
Fax: (301) 451–2043; e-mail:
khanm@csr.nih.gov.
VIII. Other Information
Technical Assistance Workshops
The IHS and NIH intend to conduct
technical assistance and information
sharing workshops about this grant
VerDate jul<14>2003
16:04 Apr 28, 2005
Jkt 205001
initiative in July 2005 at one regional
center. Potential grantees wanting to
attend one of these workshops will have
to provide names and the eligible
organization to Ms. Sylvia Ryan, at
telephone number (301) 443–5204 or
Fax (301) 443–9602, or by e-mail to
sryan@hqe.ihs.gov as soon as possible
and no later than March 15, 2005. This
notification will help the IHS and the
NIH to determine the best times and
locations for potential grantees’ training
and to have adequate workshop
supplies. The details of the workshops
and locations will be posted (as they are
finalized) on the IHS Research Program
Web site at https://www.ihs.gov/
medicalprograms/research.
References for Background Information
Anderson, N.B. Levels of analysis in
health science: A framework for
integrating sociobehavioral and
biomedical research. Annals of the
New York Academy of Sciences,
1998, 840, 563–576.
Ballantine, B., Ballantine, I. (Eds.),
Thomas, D.H., Miller, J., White, R.,
Nabokov, P., Deloria, P.J. (Text by),
Joseph, A.M. (Intro.) The Native
Americans: An Illustrated History.
Turner Publishing, Inc. Atlanta, GA,
1993.
Freeman, W.L. The role of community
in research with stored tissue
samples. Weir R (Ed.) Stored tissue
samples: Ethical, legal, and public
policy implications. University
IowaPress. Iowa City, IA, 1998, 267301.
Gazmararian, J.A., Baker, D.W.,
Williams, M.V., Parker, R.M., Scott,
T.L., Green, D.C., Fehrenbach, S.N.,
Ren, J. & Koplan, J.P. Health literacy
among Medicare enrollees in a
managed care organization. Journal of
the American Medical Association,
1999, 281, 545–551.
Haynes, M.A. & Smedley, B.D. (Eds.)
The Unequal Burden of Cancer: An
Assessment of NIH Programs for
Ethnic Minorities and the Medically
Underserved. Institute of Medicine.
National AcademyPress. Washington,
DC, 1999.
Macaulay, A.C., Commanda, L.E.,
Freeman, W.L., Gibson, N., McCabe,
M.L., Robbins, C.M., & Twohig, P.L.,
(for the) North American Primary Care
Research Group. Participatory
research maximizes community and
lay involvement. British Medical
Journal, 1999, 319, 774–778.
Minority Economic Profiles. U.S.
Bureau of the Census, Population
Division. Issued July 24, 1992. (Tables
1990 CPH–L–92, 93, 94 and 95).
NIH Publication 98–4247. Women of
Color Health Data Book. Office of
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
22351
Research On Women’s Health, Office
of the Director, National Institutes of
Health, 1998.
Trends in Indian Health 1998–99.
Program Statistics Team, Office of
Public Health, Indian Health Service,
2001.
Regional Differences in Indian Health
1998–99. Program Statistics Team,
Office of Public Health, Indian Health
Service, 2000.
Weiss, B.D., Reed, R.L., & Kligman, E.W.
Literary skills and communication
methods of low-income older persons.
Patient Education and Counseling,
1995, 25, 109–119.
Williams, D.R. & Collins, C. U.S.
Socioeconomic and Racial Differences
in Health: Patterns and Explanations.
Annual Review of Sociology, 1995,
21, 349–386.
Williams, M.V., Parker, R.M., Baker,
D.W., Parikh, N.S., Pitkin, K., Coates,
W.C., & Nurss, J.R. Inadequate
functional health literacy among
patients at two public hospitals.
Journal of the American Medical
Association, 1995, 274, 1677–1682.
Dated: April 22, 2005.
Charles Grim,
Assistant Surgeon General Director, Indian
Health Service.
[FR Doc. 05–8465 Filed 4–28–05; 8:45 am]
BILLING CODE 4165–16–U
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: (301)
496–7057; fax: (301) 402–0220. A signed
E:\FR\FM\29APN1.SGM
29APN1
22352
Federal Register / Vol. 70, No. 82 / Friday, April 29, 2005 / Notices
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Standard Slide for Testing the Axial
Resolution of Microscopes
Edward Cho and Stephen Lockett (NCI/
SAIC—Frederick)
DHHS Reference No. E–148–2005/0—
Research Tool
Licensing Contact: Michael Shmilovich;
301/435–5019;
shmilovm@mail.nih.gov
Available for licensing as a research
tool for both internal use or commercial
distribution is a test slide for threedimensional resolution. The U.S.
Government has not applied for patent
rights on this invention. The resolution
of an optical system must be accurately
measured in multiple dimensions when
acquiring imaging data for biological or
materials applications. Such
measurements permit quantitative
analysis of data obtained from the
optical system. The invention is a
microscope slide that can be adapted for
a variety of microscopy applications
(e.g., electron, confocal, widefield
fluorescence, and deconvolution) to
measure and resolve multiple points or
objects in three-dimensional space by
having objects of known distances
separated in three dimensions. The slide
is ideally suited to test the precision of
the resolution of an optical system to
determine the quality of the optical
system and its separate components.
This allows for proper quality control of
existing instruments, as well as a
method to evaluate instruments that are
being considered for purchase. The slide
is designed with markings having
known distances to determine
resolution and allows for the
quantification of spatial data.
Use of Targeted Bone Marrow Cell
Infiltration To Induce Pigmentation and
Hair Growth in Skin
Riccardo Cassiani-Ingoni (NINDS); U.S.
Provisional Application filed 18 Mar
2005
(DHHS Reference No. E–343–2004/0–
US–01)
Licensing Contact: Fatima Sayyid; (301)
435–4521; sayyidf@mail.nih.gov
A long standing problem in skin
research has been the difficulty of
inducing stem cells such as bone
marrow cells, to infiltrate the skin. Such
infiltration could be the basis of
numerous therapeutic intraventions.
The present invention describes a
method of using localized inflammation
to induce targeted bone marrow cell
effects in the skin. Among the
conditions treated in the preliminary
trials are hair and pigmentation loss.
VerDate jul<14>2003
16:04 Apr 28, 2005
Jkt 205001
Alopecia (hair loss) is a common
condition that results from diverse
causes such as altered physiology,
surgical trauma and/or certain drugs.
The present invention relates to
methods of increasing hair growth and
melanocyte proliferation. Such methods
include administration of bone marrow
cells, an agent that mobilizes bone
marrow cells or a combination thereof.
mesenchymal-epithelial conversion,
kidney development, and kidney
tumorigenesis. It may also have future
application in the development of renal
xenographs or other forms of kidney
tissue transplantation.
Creation and Characterization of
Carcinogen-Altered Mouse Epidermal
CellLines
Adam B. Glick (NCI)
DHHS Reference No. E–300–1999/0—
Research Tool.
Licensing Contact: Marlene Shinn-Astor;
(301) 435–4426; shinnm@mail.nih.gov
Many human cancers and other skin
ailments arise from overexpression of
the polypeptide TGFbeta1 growth factor.
This growth factor is a growth inhibitor
whose function involves cell
differentiation and development. It is
thought that overexpression of this
protein is a contributing factor in many
diseases, including certain cancers and
dermal fibrosis.
There is a need for mouse models that
can exhibit overexpression of TGFbeta1
in a locally specific manner. Such is the
technology being made available. The
technology relates to a mouse model
where the overexpression in epithelial
cells is achieved via the bigenic
tetracycline regulatory system.
Expression of tetO TGFbeta1 occurs
when the mice are bred with a second
transgenic line expressing the
transactivator tTa or rTa. The rTa or tTa
have been coupled with keratin 5
promoters, enabling localized activation
of tetO TGFbeta1 in the presence or
absence of tetracyclines upon successful
mating. The potential uses of these
models is invaluable and can assist
similar research involving different
tissue specificity.
Stuart H. Yuspa (NCI)
DHHS Reference No. E–154–2004/0—
Research Tool
Licensing Contact: Jesse S. Kindra; (301)
435–5559; kindraj@mail.nih.gov
The invention relates to the creation
of three (3) cell lines that may be used
as models of putative initiated cancer
cells. The cell lines can be used in basic
research assays and low/high
throughput screening assays.
Cell line 308 evolved from a calciumresistant focus from adult mouse
epidermis that was exposed to the
carcinogen, 7,12dimethylbenz[a]anthracene (DMBA).
Cell lines F and D were derived by
treating primary newborn mouse
epidermal cells in culture with Nmethyl-N’-nitro-N-nitrosoguanidine
(MNNG) and DMBA, respectively. These
three (3) nontumorigenic cell lines
derived from differentiation-resistant,
carcinogen-induced foci may be
considered to be putative initiated cells.
The creation and characterization of
the cell lines was published in Yuspa
and Morgan, 1981, ‘‘Mouse Skin Cells
Resistant to Terminal Differentiation
Associated with Initiation of
Carcinogenesis,’’ Nature, vol. 72–74;
and Hennings et al., 1987, ‘‘Response of
Carcinogen-Altered Mouse Epidermal
Cells to Phorbol Ester Tumor Promoters
and Calcium,’’ The Society for
Investigative Dermatology, Inc., vol. 88,
no. 1, 60–65.
Conditionally Immortalized Cell Line of
Metanephric Mesenchyme
Zoia B. Levashova et al. (NCI)
DHHS Reference No. E–181–2001/0—
Research Tool
Licensing Contact: Marlene Shinn-Astor;
(301) 435–4426; shinnm@mail.nih.gov
An immortalized rat cell line with
characteristics of undifferentiated
kidney blastemal cells has been
established (Kidney Int. 60:2075, 2003).
Not only can these cells be maintained
in culture, but they retain the capacity
to differentiate into epithelial-like cells.
This cell line may have utility in
studying the molecular mechanisms of
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
A Transgenic Mouse Model for
Tetracycline Regulation of Active
TGFbeta1 in Mice: tetO TGFbeta1
Dated: April 14, 2005.
Steven M. Ferguson,
Director, , Division of Technology
Development and Transfer, Office of
Technology Transfer, National Institutes of
Health.
[FR Doc. 05–8546 Filed 4–28–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
E:\FR\FM\29APN1.SGM
29APN1
]]>Agencies
[Federal Register Volume 70, Number 82 (Friday, April 29, 2005)]
[Notices]
[Pages 22351-22352]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-8546]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A
signed
[[Page 22352]]
Confidential Disclosure Agreement will be required to receive copies of
the patent applications.
Standard Slide for Testing the Axial Resolution of Microscopes
Edward Cho and Stephen Lockett (NCI/SAIC--Frederick)
DHHS Reference No. E-148-2005/0--Research Tool
Licensing Contact: Michael Shmilovich; 301/435-5019;
shmilovm@mail.nih.gov
Available for licensing as a research tool for both internal use or
commercial distribution is a test slide for three-dimensional
resolution. The U.S. Government has not applied for patent rights on
this invention. The resolution of an optical system must be accurately
measured in multiple dimensions when acquiring imaging data for
biological or materials applications. Such measurements permit
quantitative analysis of data obtained from the optical system. The
invention is a microscope slide that can be adapted for a variety of
microscopy applications (e.g., electron, confocal, widefield
fluorescence, and deconvolution) to measure and resolve multiple points
or objects in three-dimensional space by having objects of known
distances separated in three dimensions. The slide is ideally suited to
test the precision of the resolution of an optical system to determine
the quality of the optical system and its separate components. This
allows for proper quality control of existing instruments, as well as a
method to evaluate instruments that are being considered for purchase.
The slide is designed with markings having known distances to determine
resolution and allows for the quantification of spatial data.
Use of Targeted Bone Marrow Cell Infiltration To Induce Pigmentation
and Hair Growth in Skin
Riccardo Cassiani-Ingoni (NINDS); U.S. Provisional Application filed 18
Mar 2005
(DHHS Reference No. E-343-2004/0-US-01)
Licensing Contact: Fatima Sayyid; (301) 435-4521; sayyidf@mail.nih.gov
A long standing problem in skin research has been the difficulty of
inducing stem cells such as bone marrow cells, to infiltrate the skin.
Such infiltration could be the basis of numerous therapeutic
intraventions. The present invention describes a method of using
localized inflammation to induce targeted bone marrow cell effects in
the skin. Among the conditions treated in the preliminary trials are
hair and pigmentation loss.
Alopecia (hair loss) is a common condition that results from
diverse causes such as altered physiology, surgical trauma and/or
certain drugs. The present invention relates to methods of increasing
hair growth and melanocyte proliferation. Such methods include
administration of bone marrow cells, an agent that mobilizes bone
marrow cells or a combination thereof.
Creation and Characterization of Carcinogen-Altered Mouse Epidermal
CellLines
Stuart H. Yuspa (NCI)
DHHS Reference No. E-154-2004/0--Research Tool
Licensing Contact: Jesse S. Kindra; (301) 435-5559;
kindraj@mail.nih.gov
The invention relates to the creation of three (3) cell lines that
may be used as models of putative initiated cancer cells. The cell
lines can be used in basic research assays and low/high throughput
screening assays.
Cell line 308 evolved from a calcium-resistant focus from adult
mouse epidermis that was exposed to the carcinogen, 7,12-
dimethylbenz[a]anthracene (DMBA). Cell lines F and D were derived by
treating primary newborn mouse epidermal cells in culture with N-
methyl-N'-nitro-N-nitrosoguanidine (MNNG) and DMBA, respectively. These
three (3) nontumorigenic cell lines derived from differentiation-
resistant, carcinogen-induced foci may be considered to be putative
initiated cells.
The creation and characterization of the cell lines was published
in Yuspa and Morgan, 1981, ``Mouse Skin Cells Resistant to Terminal
Differentiation Associated with Initiation of Carcinogenesis,'' Nature,
vol. 72-74; and Hennings et al., 1987, ``Response of Carcinogen-Altered
Mouse Epidermal Cells to Phorbol Ester Tumor Promoters and Calcium,''
The Society for Investigative Dermatology, Inc., vol. 88, no. 1, 60-65.
Conditionally Immortalized Cell Line of Metanephric Mesenchyme
Zoia B. Levashova et al. (NCI)
DHHS Reference No. E-181-2001/0--Research Tool
Licensing Contact: Marlene Shinn-Astor; (301) 435-4426;
shinnm@mail.nih.gov
An immortalized rat cell line with characteristics of
undifferentiated kidney blastemal cells has been established (Kidney
Int. 60:2075, 2003). Not only can these cells be maintained in culture,
but they retain the capacity to differentiate into epithelial-like
cells. This cell line may have utility in studying the molecular
mechanisms of mesenchymal-epithelial conversion, kidney development,
and kidney tumorigenesis. It may also have future application in the
development of renal xenographs or other forms of kidney tissue
transplantation.
A Transgenic Mouse Model for Tetracycline Regulation of Active TGFbeta1
in Mice: tetO TGFbeta1
Adam B. Glick (NCI)
DHHS Reference No. E-300-1999/0--Research Tool.
Licensing Contact: Marlene Shinn-Astor; (301) 435-4426;
shinnm@mail.nih.gov
Many human cancers and other skin ailments arise from
overexpression of the polypeptide TGFbeta1 growth factor. This growth
factor is a growth inhibitor whose function involves cell
differentiation and development. It is thought that overexpression of
this protein is a contributing factor in many diseases, including
certain cancers and dermal fibrosis.
There is a need for mouse models that can exhibit overexpression of
TGFbeta1 in a locally specific manner. Such is the technology being
made available. The technology relates to a mouse model where the
overexpression in epithelial cells is achieved via the bigenic
tetracycline regulatory system. Expression of tetO TGFbeta1 occurs when
the mice are bred with a second transgenic line expressing the
transactivator tTa or rTa. The rTa or tTa have been coupled with
keratin 5 promoters, enabling localized activation of tetO TGFbeta1 in
the presence or absence of tetracyclines upon successful mating. The
potential uses of these models is invaluable and can assist similar
research involving different tissue specificity.
Dated: April 14, 2005.
Steven M. Ferguson,
Director, , Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 05-8546 Filed 4-28-05; 8:45 am]
BILLING CODE 4140-01-P
